Purpose: High levels of bone morphogenetic protein (BMPs) have been reported in patients with lung cancer.This study was conducted to assess correlations between serum BMP-2 levels and prognostic outcome in patientswith non-small-cell lung cancer (NSCLC).
Methods: Blood samples from 84 patients with advanced NSCLCand 42 healthy controls were analyzed and quantitated for serum BMP-2 levels before and after two cycles ofchemotherapy using a commercially available ELISA kit.
Results: The median level of BMP-2 was 146.9 pg/ml in patients with NSCLC vs. 87.7 pg/ml in healthy controls (P<0.01). A significant correlation was observedbetween pretreatment serum BMP-2 level and ECOG PS, disease stage and number of organs with metastases(P<0.05). Serum BMP-2 level decreased significantly in patients who achieved objective response after twocycles of chemotherapy. Multivariate analysis showed that increased BMP-2 level and advanced clinical stagewere significantly correlated with poor prognosis.
Conclusion: Thes erum BMP-2 level is positively correlatedwith clinical stage, ECOG PS and metastatic burden and may serve as an independent negative predictor forprognosis. Decreased BMP-2 after chemotherapy could be a reliable marker for efficacy of treatment.